OneSource Pharma's Bengaluru Unit II has been granted a renewal of its EU Good Manufacturing Practice (GMP) certification. This facility focuses on producing biologics, drug-device combinations, and sterile injectables.

Despite facing challenges, Onesource Specialty remains optimistic about achieving a $400 million revenue by the end of fiscal year 2028, demonstrating resilience amidst uncertainties.